Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Are selective cyclo-oxygenase 2 inhibitors safe after coronary artery bypass grafting surgery?

Nature Clinical Practice Cardiovascular Medicine volume 2, pages 504–505 (2005)Cite this article

boxed-textNussmeier NA et al. (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352: 1081–1091

COX inhibitors and traditional NSAIDs should be avoided in patients after coronary artery bypass grafting surgery

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ott E et al. (2003) Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 125: 1481–1492

    Article  CAS  Google Scholar 

  2. Whelton A (online 7 March 2005) Safety of parecoxib and valdecoxib in the treatment of postoperative pain following coronary artery bypass graft surgery or major general surgery [http://www.acc05online.acc.org/highlights/keyLectures.aspx?sessionId=8030&date=7] (accessed 15 August 20005)

  3. Mukherjee D et al. (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286: 954–959

    Article  CAS  Google Scholar 

  4. Bresalier RS et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092–1102

    Article  CAS  Google Scholar 

  5. Solomon SD et al. (2005) Cardiovascular risk associated with Celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071–1080

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Hannah Camm, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. a Consultant and the Head of the Coronary Care Unit in the Department of Cardiology at the University Clinic of Zurich, Switzerland

    Frank Ruschitzka

Authors
  1. Frank Ruschitzka
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frank Ruschitzka.

Ethics declarations

Competing interests

F Ruschitzka has received grants and served as a consultant for Aventis, Merck, Novartis and Pfizer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ruschitzka, F. Are selective cyclo-oxygenase 2 inhibitors safe after coronary artery bypass grafting surgery?. Nat Rev Cardiol 2, 504–505 (2005). https://doi.org/10.1038/ncpcardio0318

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0318

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing